Answers are grounded in this paper and cite their sources.
Purpose: The clinical implications of the metabolic parameters of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET/CT) in epidermal growth factor receptor ( EGFR) -mutated lung cancer are not fully understood. The aim of this study was to evaluate the diagnostic and prognostic utility of the parameters in EGFR -mutated lung cancer patients. Patients and Methods: We retrospectively enrolled 134 patients with advanced lung adenocarcinoma (72 EGFR -negative and 62 EGFR- positive). We evaluated the correlation between EGFR mutational status and the maximum standardized uptake value (SUVmax), as well as the associations between treatment outcomes in EGFR -mutated patients and various metabolic parameters of primary tumors. For the best predictive parameters, we calculated the metabolic tumor volume (MTV) and total lesion glycolysis (TLG) using two SUV cutoffs: 1.5 (MTV 1.5 , TLG 1.5 ) and 2.5 (MTV 2.5 , TLG 2.5 ). Results: Mean SUVmax was lower for EGFR -mutated tumors compared with EGFR wild-type (6.11 vs 10.41, p < 0.001) tumors. Low SUVmax was significantly associated with positive EGFR mutation (odds ratio = 1.74). Multivariate analysis for survival demonstrated that high MTV 1.5 , TLG 1.5 , MTV 2.5 , and TLG 2.5 were independently associated with shorter progression-free survival (PFS) and overall survival (OS), and the highest hazard ratios were found in TLG 1.5 (3.26 for PFS and 4.62 for OS). Conclusion: SUVmax may be predictive for EGFR mutational status, and MTV and TLG of primary tumors may be promising prognostic parameters; 18 F-FDG PET/CT has potential utility for the risk stratification of EGFR -mutated patients treated with targeted therapy.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: